MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
49.48
+0.60
+1.23%
Closed 16:01 02/23 EST
OPEN
48.78
PREV CLOSE
48.88
HIGH
50.22
LOW
48.75
VOLUME
454.39K
TURNOVER
0
52 WEEK HIGH
54.98
52 WEEK LOW
31.52
MARKET CAP
4.07B
P/E (TTM)
-5.9985
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RARE last week (0219-0223)?
Weekly Report · 1h ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. Granted 10,995 restricted stock units to nine newly hired non-executive officers of the company. The company is a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases.
Barchart · 2d ago
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $111
Benzinga · 4d ago
Ultragenyx Pharmaceutical: A Strong Buy on Robust Crysvita Sales and Promising Pipeline Prospects
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) and set a price target of $111.00. The company's promising pipeline is expected to generate a series of catalysts in 2024.
TipRanks · 4d ago
Weekly Report: what happened at RARE last week (0212-0216)?
Weekly Report · 02/19 09:29
Wall Street Analysts Are Bullish on Top Healthcare Picks
Ultragenyx Pharmaceutical (RARE – Research Report), NeoGenomics and Shockwave Medical have been recommended by 3 analysts with bullish sentiments. Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Ultragenyx pharmaceutical on February 15. The company's shares closed at $48.92.
TipRanks · 02/19 04:50
Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $48
Benzinga · 02/16 13:55
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Ultragenyx Pharmaceutical (RARE) and West Pharmaceutical Services (WST)
TipRanks · 02/16 13:40
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company's clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.